Japan’s Ministry of Health, Labor and Welfare (MHLW) approved label expansion for AbbVie’s JAK inhibitor Rinvoq (upadacitinib).
AbbVie announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for Rinvoq (upadacitinib) in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
AbbVie announced Rinvoq (upadacitinib 15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase III study of Rinvoq in atopic dermatitis.
AbbVie announced the European Commission (EC) approved Rinvoq (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent
The National Institute for Health and Care Excellence (NICE) has recommended Rinvoq (upadacitinib) from AbbVie together with standard-of-care methotrexate, for...
AbbVie has announced that the FDA has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for...
AbbVie announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for Rinvoq (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with active ankylosing spondylitis.
Abbvie has filed its JAK inhibitor Rinvoq (upadacitinib) in Japan for an additional indication of non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients who have responded inadequately to existing treatments.